Treatment of Primary Neoplasms of Lymphoid Tissues

  • Saul A. Rosenberg
Part of the Comprehensive Immunology book series (COMIMUN, volume 4)

Abstract

A discussion of the management of adult patients with primary neoplasms of lymphoid tissues cannot be separated from a recognition of problems and controversies in nomenclature and classification. Clinicians are faced with the challenge of understanding and judging numerous histopathological proposals and new immunological and lymphoid physiological concepts at the same time as rapidly changing diagnostic and therapeutic programs are being developed and proposed. The experienced clinician is constantly aware, by observing patients with these diseases, that current and proposed understanding of the nature of lymphoid neoplasms is still imprecise and inadequate. Yet, despite the apparent confusion and complexity of this field to the student or the inexperienced, the situation is improving. Advances are being made in predicting clinical behavior and treatment responses based on good clinicopathological correlative studies and insights. As a result, the management of patients with neoplasms of lymphoid tissues is among the most rewarding and satisfying in the difficult area of clinical oncology.

Keywords

Leukemia Radium Neuropathy Oncol Doxorubicin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alsenberg, A. C., 1965, Lymphocytopenia in Hodgkin’s disease, Blood 25: 1037–1042.Google Scholar
  2. Arseneau, J. C., Sponzo, R. W., Levin, D. L., Schnipper, L. E., Bonner, H., Young, R. C., Canellos, G. P., Johnson, R. E., and DeVita, V. T., 1972, Nonlymphomatous malignant tumors complicating Hodgkin’s disease, N. Engl J. Med. 287: 1119–1122.PubMedCrossRefGoogle Scholar
  3. Berard, C. W., and Dorfman, R. F., 1974, Histopathology of malignant lymphomas, in: Clinics in Haematology (S. Rosenberg, guest ed.), 3: 39–76.Google Scholar
  4. Bernard, J., Chiappa, S., Denoix, P., Kaplan, H. S., Laugier, A., Lukes, R. J., Mathe, G., Nezeloff, G., Peters, V., Ratti, A., and Tubiana, M., 1966, Proposition d’une classification des différentes formes cliniques de la maladie de Hodgkin, Nouv. Rev. Franc. Hemat. 6: 175–176.Google Scholar
  5. Bonadonna, F., DeLena, M., Lattuada, A., Milani, F., Monfardini, S., and Baretta, G., 1975, Combination chemotherapy and radiotherapy in non-Hodgkin’s lymphomata, Br. J. Cancer 31 (Suppl. II): 481–488.Google Scholar
  6. Bouroncle, B. A., 1966, Sternberg-Reed cells in the peripheral blood of patients with Hodgkin’s disease, Blood 27: 544–556.PubMedGoogle Scholar
  7. Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., and Tubiana, M., 1971, Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 31: 1860–1861.PubMedGoogle Scholar
  8. Davidson, J. W., and Clarke, E. A., 1968, Influence of modem radiological techniques on clinical staging of malignant lymphomas, Can. Med. Assoc. J. 99: 1196–1204.PubMedGoogle Scholar
  9. DeVita, V. T., Serpick, A., and Carbone, P. P., 1970, Combination chemotherapy in the treatment of advanced Hodgkin’s disease, Ann. Intern. Med. 73: 881–895.PubMedGoogle Scholar
  10. DeVita, V. T., Jr., Canellos, G. P., Chabner, B., Schein, P., Hubbard, S. P., and Young, R. C., 1975, Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1: 248–250.PubMedCrossRefGoogle Scholar
  11. DeVita, V. T., CaneUos, G., Hubbard, S., Chabner, B., and Young, R., 1976, Chemotherapy of Hodgkin’s disease (HD) with MOPP: A ten year progress report, Proc. Am. Assoc. Cancer Res., Am. Soc. Clin. Oncol. 17: 269 (Abs. C-131).Google Scholar
  12. Easson, E. C., and Russell, M. H., 1963, The cure of Hodgkin’s disease, Br. Med. J. 1: 1704–1707.PubMedCrossRefGoogle Scholar
  13. EzdinH, E. Z., Sokal, J. E., Aungst, C. W., Kim, U., and Sandberg, A. A., 1969, Myeloid leukemia in Hodgkin’s disease: Chromosomal abnormalities, Ann. Intern. Med. 71: 1097–1104.Google Scholar
  14. Gilbert, R., 1939, Radiotherapy in Hodgkin’s disease (malignant granulomatosis). Am. J. Roentgenol. Radium Ther. 41: 198–241.Google Scholar
  15. Glatstein, E., Guernsey, J. M., Rosenberg, S. A., and Kaplan, H. S., 1969, The value of laparotomy and splenectomy in the staging of Hodgkin’s disease. Cancer 24: 709–718.PubMedCrossRefGoogle Scholar
  16. Glicksman, A. S., and Nickson, J. J., 1973, Acute and late reactions to irradiation in the treatment of Hodgkin’s disease. Arch. Intern. Med. 131: 369–373.PubMedCrossRefGoogle Scholar
  17. Goffinet, D. R., Castellino, R. A., Kim, H., Dorfinan, R. F., Fuks, Z., Rosenberg, S. A., Nelsen, T., and Kaplan, H. S., 1973, Staging laparotomies in unselected previously untreated patients with non-Hodgkin’s lymphomas. Cancer 32: 672–681.PubMedCrossRefGoogle Scholar
  18. Grann, V., Pool, J. L., and Mayer, K., 1966, Comparative study of bone marrow aspiration and biopsy in patients with neoplastic disease. Cancer 19: 1898–1900.PubMedCrossRefGoogle Scholar
  19. Hoster, H. A., Dratman, M. B., Craver, L. F., and Rolnick, H. A., 1948, Hodgkin’s disease, (Part 1) 1832–1947, Cancer Res. 8: 1–78.PubMedGoogle Scholar
  20. Jackson, H., Jr., and Parker, F., Jr., 1947, Hodgkin’s Disease and Allied Disorders, Oxford University Press, New York.Google Scholar
  21. Johnson, R. E., 1969, Modem approaches to the radiotherapy of lymphoma, Semin. Hematol. 6: 357–375.PubMedGoogle Scholar
  22. Johnson, R. E., 1975, Management of generalized malignant lymphomata with “systemic” radiotherapy, Br. J. Cancer 31 (Suppl. II): 450–455.Google Scholar
  23. Jones, S. E., Fuks, Z., Bull, M., Kadin, M. D., Dorfman, R. F., Kaplan, H. S., Rosenberg, S. A., and Kim, H., 1973a, Non-Hodgkin’s lymphomas. IV. Clinicopathologic correlation in 405 cases, Cancer 31: 806–823.PubMedCrossRefGoogle Scholar
  24. Jones, S. E., Fuks, Z., Kaplan, H. S., and Rosenberg, S. A., 1973b, Non-Hodgkin’s lymphomas. V. Results of radiotherapy. Cancer 32: 682–691.PubMedCrossRefGoogle Scholar
  25. Kaplan, H. S., 1962, The radical radiotherapy of regionally localized Hodgkin’s disease, Radiology 78: 553–561.PubMedGoogle Scholar
  26. Kaplan, H. S., 1966, Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin’s disease, Cancer Res. 26: 1221–1224.PubMedGoogle Scholar
  27. Kaplan, H. S., 1972, Hodgkin’s Disease, Harvard University Press, Cambridge.Google Scholar
  28. Levitt, M., Marsh, J. C., DeConti, R. C., Mitchell, M. S., Skeel, R. T., Farber, L. R., and Bertino, J. R., 1972, Combination sequential chemotherapy in advanced reticulum cell sarcoma, Cancer 29: 630–636.PubMedCrossRefGoogle Scholar
  29. Lukes, R. J., and Collins, R. D., 1975, New approaches to the classification of the lymphomata, Br. J. Cancer 31 (Suppl. II): 1–28.CrossRefGoogle Scholar
  30. Lukes, R. J., and Butler, J. J., and Hicks, E. B., 1966a, Natural history of Hodgkin’s disease as related to its pathologic picture, Cancer 19: 317–344.CrossRefGoogle Scholar
  31. Lukes, R. J., Craver, L. P., Hall, T. C., Rappaport, H., and Rubin, P., 1966b, Report of the Nomenclature Committee, Cancer Res. 26: 1311.Google Scholar
  32. Neiman, R. S., Rosen, P. J., and Lukes, R. J., 1973, Lymphocyte-depletion Hodgkin’s disease: A clinicopathological entity, N. Engl. J. Med. 288: 751–755.PubMedCrossRefGoogle Scholar
  33. O’ConneU, M. J., Wiemik, P. H., Brace, K. C., Byhardt, R. W., and Greene, W. H., 1975, A combined modality approach to the treatment of Hodgkin’s disease: Preliminary results of a prospectively randomized clinical trial. Cancer 35: 1055–1065.CrossRefGoogle Scholar
  34. Olweny, C. L. M., Mbidde, E. K., Nkwocha, J., Magrath, I., and Ziegler, J. L., 1974, Chemotherapy of Hodgkin’s disease. Lancet 2: 1397.PubMedCrossRefGoogle Scholar
  35. Page, V., Gardner, A., and Karzmark, C. J., 1970, Physical and dosimetric aspects of the radiotherapy of malignant lymphomas, I. The mantle technique. II. The inverted Y technique. Radiology 96: 609–626.PubMedGoogle Scholar
  36. Peters, M. V., 1950, A study of survivals in Hodgkin’s disease treated radiologically. Am. J. Roentgenol. 63: 299–311.Google Scholar
  37. Portlock, C. S., and Rosenberg, S. A., 1976, Combination chemotherapy with cyclophosphamide, vincristine and prednisone in advanced non-Hodgkin’s lymphomas. Cancer 37: 1275–1282.PubMedCrossRefGoogle Scholar
  38. Portlock, C. S., Rosenberg, S. A., Glatstein, E., and Kaplan, H. S., 1976, Treatment of advanced non-Hodgkin’s lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47: 747–756.PubMedGoogle Scholar
  39. Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., and Pastemack, B. S., 1975, Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234.PubMedGoogle Scholar
  40. Rappaport, H., 1966, Tumors of the hematopoietic system, in: Atlas of Tumor Pathology, Section HI, Fascicle 8, pp. 91–156, Armed Forces Institute of Pathology, Washington, D.C.Google Scholar
  41. Ribas–Mundo, M., and Rosenberg, S. A., 1977 (unpublished).Google Scholar
  42. Robb-Smith, A. H. T., 1938, Reticulosis and reticulosarcoma: A histologic classification, J. Pathol. Bacteriol. 47: 457–480.CrossRefGoogle Scholar
  43. Rosenberg, S. A., 1966, Report of the committee on the staging of Hodgkin’s disease. Cancer Res. 26: 1310.Google Scholar
  44. Rosenberg, S. A., 1971, Hodgkin’s disease of the bone marrow, Cancer Res. 31: 1733–1736.PubMedGoogle Scholar
  45. Rosenberg, S. A., 1972, Splenectomy in the management of Hodgkin’s disease, Br. J. Haematol. 23: 271–276.PubMedGoogle Scholar
  46. Rosenberg, S. A., 1975, Bone marrow involvement in the non-Hodgkin’s lymphomata, Br. J. Cancer 31 (Suppl. II): 261–264.Google Scholar
  47. Rosenberg, S. A., and Kaplan, H. S., 1966, Evidence for an orderly progression in the spread of Hodgkin’s disease. Cancer Res. 26: 1225–1231.PubMedGoogle Scholar
  48. Rosenberg, S. A., and Kaplan, H. S., 1975a, The management of stages I, II, and III Hodgkin’s disease with combined radiotherapy and chemotherapy. Cancer 35: 55–63.PubMedCrossRefGoogle Scholar
  49. Rosenberg, S. A., and Kaplan, H. S., 1975b, Clinical trials in the non-Hodgkin’s lymphomata at Stanford University: Experimental design and preliminary results, Br. J. Cancer 31 (Suppl. II): 456–464.Google Scholar
  50. Rosenberg, S. A., Kaplan, H. S., Glatstein, E. J., and Portlock, C. S., 1978, Combined modality therapy of Hodgkin’s disease: A report on the Stanford trials.Cancer (in press).Google Scholar
  51. Schein, P. S., Chabner, B. A., Canellos, G. P., Young, R. C., Berard, C., and DeVita, V. T., Jr., 1974, Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin’s lymphomas. Blood 43: 181–189.PubMedGoogle Scholar
  52. Schein, P. S., Chabner, B. A., Canellos, G. P., Young, R. C., and DeVita, V. T., 1975, Non-Hodgkin’s lymphoma: Patterns of relapse from complete remission after combination chemotherapy. Cancer 35: 354–357.PubMedCrossRefGoogle Scholar
  53. Teillet, F., Boiron, M., and Bernard, J., 1971, A reappraisal of clinical and biological signs in staging of Hodgkin’s disease. Cancer Res. 31: 1723–1729.PubMedGoogle Scholar
  54. Ultmann, J. E., 1970, Current status: The management of lymphoma, Semin. Hematol. 7: 441–460.Google Scholar
  55. Warthin, A. S., 1931, The genetic neoplastic relationships of Hodgkin’s disease, aleukemic and leukemic lymphoblastoma and mycosis fungoides, Ann. Surg. 93: 153–161.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1978

Authors and Affiliations

  • Saul A. Rosenberg
    • 1
  1. 1.Division of OncologyStanford University School of MedicineStanfordUSA

Personalised recommendations